Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 May 27;26(8):1184–1198. doi: 10.1111/hiv.70050

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2025 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Network map of DC‐AEs at 48 weeks. Node size is proportional to the number of participants across all included studies for an intervention, and line thickness is proportional to the number of studies that compared the two interventions. B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; bPI, boosted protease inhibitor; CAB + RPV, cabotegravir + rilpivirine; DC‐AEs, discontinuation due to adverse events; DTG, dolutegravir; DTG/ABC/3TC, dolutegravir/abacavir/lamivudine; DTG/RPV, dolutegravir/rilpivirine; E/C/F/TXF, elvitegravir/cobicistat/emtricitabine/(tenofovir disoproxil fumarate or tenofovir alafenamide); NRTI, nucleoside reverse transcriptase inhibitor; Q4W, every 4 weeks; Q8W, every 8 weeks.